secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2023-01-27T23:59:59+00:00
Accession:  0001193125-23-017551
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo files Zymergen Q3 2022 financials; net loss $75.7M on $2.3M revenue
--------------------------------------------------------------------------

- Zymergen Q3 2022: revenue $2.3M, net loss $75.7M, operating loss $75.3M.
- Nine-month 2022: revenue $9.7M, net loss $264.3M, operating loss $245.1M.
- Cash $153.4M at Sep 30, 2022, down from $386.1M at Dec 31, 2021.
- Goodwill impairment charge of $40.6M recorded during 2022.
- Going-concern doubt that existed at June 30, 2022 alleviated by Oct 19, 2022 merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000119312523017551/0001193125-23-017551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000119312523017551/d443681d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-017551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer